Elitek and Fasturtec market seen growing on rising cancer cases and TLS care

The global market for Elitek, known as Fasturtec outside the U.S., is projected to expand through 2035 as leukemia rates rise, oncology spending increases, and more hospitals manage tumor lysis syndrome. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Elitek and Fasturtec are rasburicase-based therapies used to prevent or treat high uric acid levels in cancer patients with tumor lysis syndrome. - The market is tied to oncology supportive care, where faster treatment of TLS can help reduce kidney damage in high-risk patients. - Rising cancer incidence and broader access to hospital oncology services are expected to keep demand growing through 2035.

What happened: - The Business Research Company published its Elitek or Fasturtec Including Segment Analysis Global Market Report 2026 covering market size, trends and forecasts for 2026-2035. - The report says North America held the largest regional share in 2025. - The report says Asia-Pacific is forecast to be the fastest-growing region over the next several years. - The report includes Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional coverage. - A free sample is available here. - The full report is available here.

The details: - Elitek is the U.S. brand name, and Fasturtec is the name used outside the United States. - The drug contains rasburicase and is administered intravenously. - Rasburicase converts uric acid into allantoin, which the kidneys can eliminate more easily. - The medicine is used to treat or prevent elevated uric acid linked to tumor lysis syndrome in patients receiving chemotherapy. - The therapy is especially important for patients with leukemia, lymphoma and other cancers where rapid cell breakdown can release dangerous amounts of uric acid. - The report links past market growth to higher chemotherapy use, historic rates of TLS complications, early rasburicase approvals, growth in hospital oncology services and rising cancer cases worldwide. - Future growth is expected to be driven by the global cancer burden, expansion of pediatric oncology programs, better early TLS risk assessment, more specialized oncology centers and stronger cancer supportive care. - The report highlights emerging trends including stronger supportive oncology care, broader use in TLS management, more hospital-based infusion therapies, wider pediatric oncology treatment and better chemotherapy safety protocols. - The report says leukemia growth is a major driver because TLS can occur when treatment rapidly destroys cancer cells and releases uric acid into the bloodstream. - The American Cancer Society reported in 2024 that U.S. leukemia cases rose to 62,770 from 59,610 in 2023. - Rising healthcare spending is also supporting adoption of advanced oncology treatments. - Statistics Netherlands reported that healthcare spending in the Netherlands reached about $130.70 billion in 2024, up $9.79 billion, or 8.1%, from 2023. - The report says oncology care spending is rising as chronic disease increases demand for ongoing therapy, long-term medication and frequent medical visits. - The report also says demand for rasburicase-based therapy benefits from broader healthcare budgets that improve access to advanced treatment. - New report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis and updated graphics and tables.

Between the lines: - The report frames Elitek and Fasturtec as a narrow but important drug category whose growth depends less on broad consumer demand and more on oncology treatment intensity and hospital capability. - The focus on pediatric oncology and TLS risk assessment suggests the market may expand as hospitals improve screening and supportive care protocols, not just as cancer incidence rises. - The inclusion of forecasting tools and scoring models signals that the report is aimed at investors, suppliers and healthcare strategists looking for segment-level opportunity mapping.

What's next: - Market growth will likely track cancer incidence, leukemia prevalence and the pace of oncology infrastructure expansion. - Asia-Pacific is expected to be the key growth region to watch. - Hospitals and specialized cancer centers are likely to remain the main channels for therapy use as TLS management stays tied to inpatient oncology care. - Contact details for report inquiries were provided for Saumya Sahay at The Business Research Company, including phone and email information. - The company also listed its website and social media channels for follow-up information.